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Abstract
Addressing the problem of short stature in pediatrics is challenging 
because normal somatic growth depends on a complex interaction 
between genetic, nutritional, and hormonal factors. We report a 14-year-
old girl with deceleration of growth velocity and delayed puberty but no 
other discernible neurologic or ophthalmologic symptoms or signs. 
Clonidine and insulin tolerance tests confirmed growth hormone defi-
ciency, and magnetic resonance imaging disclosed a suprasellar mass. 
This case demonstrates that growth failure may be the only early sign of 
suprasellar tumor. Rigorous pursuit of the cause of a growth disorder 
should thus be considered, as it may disclose a potentially serious but 
treatable condition. [Tzu Chi Med J 2009;21(2):161–164]
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1. Introduction
In the pediatric population, short stature has an inci-
dence of 3 in 100 [1]. The causes of growth disorder 
are diverse, as normal somatic growth depends on 
the complex interaction between genetic, nutritional, 
and hormonal factors [2]. The range of clinical condi-
tions associated with short stature is vast, making the 
task of identifying a specific diagnosis daunting. How-
ever, certain causes, such as brain tumor, may cause 
irreversible damage or death if diagnosed too late [3]. 
It is therefore absolutely necessary to examine the 
patient thoroughly and systematically think through 
an appropriate differential diagnosis. We report our 
experience with a child whose only manifestation of 
an intracranial lesion was short stature with deceler-
ated growth.
2. Case report
A 14-year-old girl was seen in our pediatric endocrine 
clinic with the chief complaint of short stature that 
had been noted in elementary school. Her height 
was 132 cm (> 3 standard deviations below the mean) 
and weight was 34 kg (2 standard deviations below 
the mean) (Fig. 1) [4]. Her target height was 159 cm 
[5]. Her 16-year-old sister was 154 cm tall and her 
12-year-old sister was 152 cm tall. The patient had 
been born at term by a normal spontaneous vaginal 
162 TZU CHI MED J  June 2009  Vol 21  No 2
delivery without perinatal insult. According to her 
teacher and family, she had no eating problems or 
emotional disturbance. She had a grade B average in 
school. She denied nausea, headache, visual distur-
bance, polyuria, or polydipsia. Her growth velocity 
was slow at less than 3 cm/year. Her breast and pubic 
hair were Tanner stage 1. A pediatric neurologist 
found no neurologic abnormalities.
Her thyroid stimulating hormone (TSH) level was 
1.42 μIU/mL, free thyroxine was 1.06 ng/dL, α-fetopro-
tein was < 2.76 ng/mL, human chorionic gonadotropin 
was 0.39 ng/mL, prolactin was 9.59 ng/mL, estradiol 
was < 10 pg/mL, luteinizing hormone was < 3 mIU/mL, 
follicle-stimulating hormone was < 2 mIU/mL, cortisol 
was 23.41 μg/dL, sodium was 144 mmol/L, potassium 
was 3.9 mmol/L, and her karyotype was 46,XX. Her 
bone age was 8.5 years. Visual fields by Goldmann 
perimetry were within normal limits. Clonidine and in-
sulin tolerance tests showed growth hormone defi-
ciency with a peak growth hormone level of 0.46 ng/mL 
(Table 1).
Magnetic resonance imaging (MRI) revealed a space-
occupying, predominantly cystic, suprasellar lesion 
with peripheral wall enhancement (Fig. 2). A crani-
opharyngioma or pilocystic astrocytoma was sus-
pected. The patient and her family refused craniotomy, 
so gamma knife surgery was performed. Therefore, 
no tissue was available for pathology examination. 
The patient was regularly followed, and MRI after 
treatment showed partial tumor regression.
3. Discussion
This case demonstrates that a sellar or suprasellar 
tumor might initially present with growth failure alone, 
without discernible neurologic and ophthalmologic 
manifestations. Intracranial tumors must be included 
in the differential diagnosis of growth disorders, even 
if the latter is the only presenting symptom.
Growth abnormality accounts for 27.6% of all diag-
noses in a pediatric endocrine clinic, where it is the 
most common presenting complaint [6]. Constitutional 
growth delay, growth hormone deficiency, systemic 
disease, dysmorphic syndromes, and poor nutrition 
are the commonest causes. Patients with heights more 
than three standard deviations below the mean are 
likely to have organic etiologies [7,8]. However, the 
possible causes are so diverse that accurate diagno-
sis is challenging, especially when patients are less 
severely affected. This is particularly true for growth 
hormone deficiency, for which there is no diagnostic 
gold standard. Stimulation tests used to assess growth 
hormone levels include insulin-induced hypoglycemia, 
arginine, levodopa, clonidine, glucagon, and exercise 
tests [9]. Some experts use a combination of two or 
three of these tests to reduce the chance of false posi-
tives. Our patient had very low peak levels of growth 
hormone on both insulin-induced hypoglycemia and 
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Fig. 1 — Patient’s growth record showing progressive de-
celeration of growth compared with the norm [4]. (The 
patient’s height and weight prior to age 11 were not 
available.)
Table 1 — Clonidine and insulin tolerance test (ITT) results
 Growth hormone level (ng/mL) Cortisol level (μg/dL) Glucose level (mg/dL)
Time (min)
 Clonidine test ITT ITT ITT
 0 0.26 0.09  83
 15  0.1  48
 30 0.14 0.18  36
 45  0.19 21.56 58
 60 0.13 0.32 24.38 53
 90 0.2 0.46 23.41 76
120 0.18 0.18  85
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clonidine tests. In addition, she had very short stat-
ure and significant delays of bone age and puberty in 
spite of normal thyroid tests. Taken together, these 
features were most compatible with chronic growth 
hormone deficiency [10].
Having demonstrated growth hormone deficiency, 
however, we must still seek a reason for the deficiency. 
Tumors in the sella or above as well as other anomalies 
of the central nervous system account for only about 
9% of patients with growth hormone deficiency [11]. 
Conversely, half of children with suprasellar or sellar 
neoplasms have growth hormone deficiency with or 
without the deficiency of other pituitary hormones 
[12]. As well as endocrine deficiencies, these tumors 
commonly present with neurologic deficits and visual 
defects [13], which is why our patient’s presentation 
is unusual. It was the growth hormone deficiency that 
directed attention to the central nervous system, 
resulting in discovery of a suprasellar mass.
The differential diagnosis of such masses is broad, 
including such disorders as craniopharyngioma, pi-
tuitary adenoma, germ cell tumor, glioma, meningi-
oma, vascular lesions, and inflammatory processes 
[14]. Craniopharyngiomas account for 80–90% of 
neoplasms arising in the pituitary region [15]. On MRI, 
their appearance depends on the proportion of the 
solid and cystic components, the contents of the cyst, 
and the amount of calcification [16]. Although large 
amounts of calcification may appear as areas of low 
signal in T1-weighted and T2-weighted images, calci-
fication is better observed by computed tomography. 
Our patient’s MRI showed a cystic suprasellar lesion 
mixed with solid components. She did not undergo 
computed tomography, so that we could not be cer-
tain that the tumor was a craniopharyngioma, al-
though it was likely.
Surgical resection is the treatment of choice for 
craniopharyngiomas, with radiation used adjuvantly 
if complete resection is not accomplished. Stereo-
tactic radiosurgery achieves tumor control in a sub-
stantial number of patients who have small volume 
lesions. It may be particularly useful for well-defined 
residual tissue after surgery or for the treatment of 
small solid recurrent tumors, especially after failure 
of conventional radiotherapy [17–19].
When a sellar or suprasellar tumor is diagnosed 
in a patient such as ours, the possibility of hormone 
deficiencies in addition to that of growth hormone 
should be considered, including TSH, thyroxine, adre-
nocorticotropic hormone, cortisol, gonadotropins, and 
gonadal steroids. Signs of diabetes insipidus should 
be searched for. The defect can be localized to the 
hypothalamus if there is a normal response to the 
administration of hypothalamic-releasing hormones 
for TSH, adrenocorticotropic hormone, or gonadotro-
pins. Pituitary function can be assessed using an in-
sulin stress test in conjunction with thyrotropin and 
gonadotropin releasing hormone tests [20].
While tumors in the suprasellar region are usually 
benign, either infiltration or a mass effect may be 
lethal. Therefore, early diagnosis is essential to avoid 
serious morbidity and mortality. Failure to consider 
the possibility of such a tumor is more likely when 
the presentation is atypical, as it was in our patient. 
A B
Fig. 2 — (A) T1-weighted sagittal image (TR 400/TE 25) without gadolinium shows a space-occupying suprasellar 
lesion with mixed solid and cystic components. The cystic portion has low signal intensity. (B) T1-weighted sagittal 
image with gadolinium reveals enhancement of the solid component of the tumor.
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The key is recognizing the likelihood of an underly-
ing organic cause in patients with severe growth fail-
ure and then conducting a thorough search for that 
underlying cause.
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